Platinum drugs-related safety profile: The latest five-year analysis from FDA adverse event reporting system data

• DOI: 10.3389/fonc.2022.1012093
• Publication Date: 2023-01-11T06:57:22Z
• Authors: Guowen Feng; Xiaodan Zhou; Jia Chen; Dan Li; Li Chen
• Keywords: Carboplatin

With the widespread application of platinum drugs in antitumor therapy, incidence drug adverse events (ADEs) is always severe. This study aimed to explore event signals Cisplatin, Carboplatin and Oxaliplatin, three widely used platinum-containing drugs, provide a reference for rational individualized clinical use.The report data from first quarter 2017 fourth 2021 were extracted FAERS database, mining risk factors relevant reports carried out using reporting odds ratio (ROR) method proportional (PRR)and comprehensive criteria (MHRA) method.A total 1853 effective obtained agents, including 558 896 Carboplatin, 399 Oxaliplatin. The involve 23 different system organs (SOCs). Cisplatin are mainly fixed on blood lymphatic diseases, gastrointestinal systemic diseases various reactions at administration site. focused respiratory system, thoracic mediastinal while Oxaliplatin concentrated nervous diseases.It was found that main systems involved common different, correlation strength with certain each different.